Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'
Alumis' lead drug program suffered a clinical setback Tuesday as the San Francisco biotech reported its TYK2 pill failed a mid-stage lupus study. The results put a damper on what has ...
Alumis CEO Martin Babler. September 1, 2026 10:24 AM EDT R&D Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward' Andrew Dunn Senior Biopharma Correspondent Alumis’ lead drug program suffered a clinical setback Tuesday as the San Francisco biotech reported its TYK2 pill failed a mid-stage … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that